Poor
Not Aligned
Patient Risk:
High
Summary
Many substantive claims (especially pravastatin-specific statements, dosing frequency, comparative interaction/metabolism claims, and symptom-specific counseling) are not supported by the provided FDA label excerpts; only a limited subset of general statin safety/atorvastatin interaction information is supported.
Category Scores
Accurate Statements
Atorvastatin can have more interaction potential with medications that strongly affect CYP3A4.
Label 7 DRUG INTERACTIONS: increased myopathy risk with strong CYP3A4 inhibitors; examples include clarithromycin, HIV protease inhibitors, itraconazole.
Muscle symptoms are potential side effects of statins.
Label 5 WARNINGS AND PRECAUTIONS / 6 ADVERSE REACTIONS: rhabdomyolysis and myopathy (skeletal muscle) discussed.
Potential effects on liver enzymes are possible side effects of statins.
Label 6 ADVERSE REACTIONS: liver enzyme abnormalities discussed under Warnings and Precautions.
Statins are generally not used during pregnancy.
Label 4.3 Pregnancy: LIPITOR may cause fetal harm; discontinue immediately if pregnancy occurs; do not administer except highly unlikely to conceive.
Unsupported Statements
Atorvastatin is typically taken once daily.
No dosing frequency content provided in the label excerpt (2 DOSAGE AND ADMINISTRATION section is not present).
Atorvastatin is metabolized largely by the liver enzyme CYP3A4.
No such quantitative/extent metabolism statement is present in the provided excerpts.
Pravastatin is a statin used to lower LDL cholesterol.
No pravastatin label information is included in the provided label sections.
Pravastatin is used to reduce cardiovascular risk.
No pravastatin label information is included in the provided label sections.
Pravastatin is also typically taken once daily.
No pravastatin dosing information is included in the provided label sections.
Pravastatin does not rely on CYP3A4 in the same way as atorvastatin.
No comparative pravastatin metabolism information is present in the provided excerpts.
Atorvastatin is often used when a larger LDL reduction is needed.
Provided indication excerpt does not include statements about 'larger LDL reduction' or intensity selection.
Pravastatin can be effective for lowering LDL cholesterol.
No pravastatin efficacy statement is present in the provided excerpts.
Atorvastatin and pravastatin differ in how they are commonly dosed.
No dosing details for either drug (and no comparative dosing) are provided in the excerpts.
Atorvastatin depends more on CYP3A4 metabolism.
The provided interaction text supports increased risk with strong CYP3A4 inhibitors but does not support comparative/extent metabolism wording.
Pravastatin tends to have a different interaction profile.
No pravastatin-specific interaction profile is included in the provided excerpts.
Certain antibiotics/antifungals can affect CYP3A4 and impact interaction risk with atorvastatin or pravastatin.
The label excerpt provides examples for atorvastatin (LIPITOR) and strong CYP3A4 inhibitors; it does not support pravastatin-specific impact.
HIV medicines can affect CYP3A4 and impact interaction risk with atorvastatin or pravastatin.
The excerpt supports HIV protease inhibitors as strong CYP3A4 inhibitors increasing myopathy risk with statins/atorvastatin context, but it does not support a pravastatin-specific claim.
Other medications that inhibit or induce CYP3A4 can affect interaction risk with atorvastatin or pravastatin.
Provided text addresses strong CYP3A4 inhibitors; it does not support induction or pravastatin-specific interaction claims.
Individual tolerance of statins varies.
No statement about variability of tolerance is present in the provided excerpts.
Muscle pain, weakness, or dark urine after starting or increasing a statin dose should prompt contact with a clinician.
No symptom-specific counseling (pain/weakness/dark urine) is present in the provided excerpts; counseling information provided is generic.
Atorvastatin is commonly prescribed in a range of strengths taken once daily.
Dosage strength/range and once-daily frequency are not supported by the provided excerpts.
Pravastatin is also prescribed once daily.
No pravastatin dosing information is present in the provided excerpts.
Pravastatin dose levels are often chosen to balance LDL reduction and tolerability.
No pravastatin dosing strategy statement is present in the provided excerpts.
Clinicians tailor starting dose and dose changes to LDL level, cardiovascular risk, age, kidney/liver status, and medication list.
No dosing/titration tailoring factors (LDL level, age, kidney status, liver status) are provided in the excerpts.
People needing more aggressive LDL lowering are often started on atorvastatin or another high-intensity statin.
Provided indication excerpt does not mention intensity-based initiation or 'high-intensity' strategy.
People at higher risk of drug–drug interactions may be steered toward pravastatin depending on their medication list.
No comparative recommendation/selection of pravastatin vs atorvastatin is provided.
If pregnancy is possible or during breastfeeding, clinician guidance is needed before taking either atorvastatin or pravastatin.
Label excerpt addresses atorvastatin pregnancy and breastfeeding; it does not mention pravastatin.
Neither atorvastatin nor pravastatin are typically the focus of brand-only patent exclusivity discussions.
No patent/exclusivity information is present in the provided label excerpts.
Atorvastatin and pravastatin are long-established medicines with generic availability in most markets.
No market-history or generic availability information is present in the provided label excerpts.
Contradictions
Important Omissions
Specific dosing frequency and administration instructions for atorvastatin and pravastatin.
Importance:
Moderate
Label-specific pravastatin indications, dosing, contraindications, warnings/precautions, and interaction details.
Importance:
Moderate
Label-accurate pregnancy and breastfeeding guidance for pravastatin (not provided in the excerpts).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Unsupported dosing-frequency and pravastatin-specific efficacy/interaction/comparative metabolism statements could mislead clinical use; symptom-specific counseling content is also not supported by the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple substantive claims are not supported by the provided FDA label excerpts, especially for pravastatin and for dosing frequency/specific symptom counseling; comparative metabolism/interaction and selection guidance are largely unsupported.
Suggested Improvement
Restrict statements to what is explicitly supported by the provided label excerpts (e.g., atorvastatin interaction risk with strong CYP3A4 inhibitors; general serious adverse reaction categories; atorvastatin pregnancy/breastfeeding language). Remove or qualify unsupported pravastatin comparative and dosing-frequency claims, and avoid symptom-specific counseling not present in the provided counseling text.